Literature DB >> 15016944

Providing treatment for hepatitis C in an Australian district centre.

A Ewart1, L Harrison, B Joyner, A Safe.   

Abstract

Hepatitis C virus (HCV) poses a major public health problem world wide. The introduction of combined therapy (interferon and ribavirin) and the recent development of pegylated interferon have offered the opportunity to alter the natural history of HCV, potentially reducing morbidity and mortality. Until recently, treatment has been confined to larger Australian cities. This paper describes the establishment of a clinic for the treatment of HCV in a regional Australian city. The facilities of the sexual health clinic were utilised. Factors contributing to the success of the clinic include the specialist nurse, a multidisciplinary approach, and the service model of shared care with general practitioners. The patient population and the outcomes of managing HCV in a regional centre are described. The sustained viral response rate is comparable to the published data from specialist centres.

Entities:  

Mesh:

Year:  2004        PMID: 15016944      PMCID: PMC1742942          DOI: 10.1136/pgmj.2003.005017

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

Review 1.  New pieces to the hepatitis C treatment puzzle.

Authors:  O Weiland
Journal:  J Hepatol       Date:  2000-09       Impact factor: 25.083

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Hepatitis C virus genotypes in Australia.

Authors:  R McCaw; L Moaven; S A Locarnini; D S Bowden
Journal:  J Viral Hepat       Date:  1997-09       Impact factor: 3.728

Review 4.  Treatment of chronic hepatitis C: a systematic review.

Authors:  Geetanjali Chander; Mark S Sulkowski; Mollie W Jenckes; Michael S Torbenson; H Franklin Herlong; Eric B Bass; Kelly A Gebo
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 5.  Optimal therapy of hepatitis C.

Authors:  Adrian M Di Bisceglie; Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

6.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

Authors:  E J Heathcote; M L Shiffman; W G Cooksley; G M Dusheiko; S S Lee; L Balart; R Reindollar; R K Reddy; T L Wright; A Lin; J Hoffman; J De Pamphilis
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

7.  Health-related quality of life in chronic liver disease: the impact of type and severity of disease.

Authors:  Z M Younossi; N Boparai; L L Price; M L Kiwi; M McCormick; G Guyatt
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

8.  Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.

Authors:  S Nishiguchi; S Shiomi; S Nakatani; T Takeda; K Fukuda; A Tamori; D Habu; T Tanaka
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

9.  Sertraline treatment of interferon-alfa-induced depressive disorder.

Authors:  T M Schramm; B R Lawford; G A Macdonald; W G Cooksley
Journal:  Med J Aust       Date:  2000-10-02       Impact factor: 7.738

  9 in total
  1 in total

1.  Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.

Authors:  Adam Isaiah Newman; Shelley Beckstead; David Beking; Susan Finch; Tina Knorr; Carol Lynch; Meredith MacKenzie; Daphne Mayer; Brenda Melles; Ron Shore
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.